Active content determination of non-coated pharmaceutical pellets by near infrared spectroscopy: Method development, validation and reliability evaluation
Near infrared spectroscopy; Process Analytical Technology; Pharmaceutical pellets; Active content; Validation; Accuracy profile; Multivariate analysis
Abstract :
[en] A robust near infrared (NIR) method able to quantify the active content of pilot non-coated pharmaceutical pellets was developed. A protocol of calibration was followed, involving 2 operators, independent pilot batches of non-coated pharmaceutical pellets and two different NIR acquisition temperatures. Prediction models based on Partial Least Squares (PLS) regression were then carried out. Afterwards, the NIR method was fully validated for an active content ranging from 80 to 120% of the usual active content using new independent pilot batches to evaluate the adequacy of the method to its final purpose. Conventional criteria such as the R2, the Root Mean Square Error of Calibration (RMSEC), the Root Mean Square Error of Prediction (RMSEP) and the number of PLS factors enabled the selection of models with good predictive potential. However, such criteria sometimes fail to choose the most fitted for purpose model. Therefore, a novel approach based on accuracy profiles of the validation results was used, providing a visual representation of the actual and future performances of the models. Following this approach, the prediction model using signal pre-treatment Multiplicative Scatter Correction (MSC) was chosen as it showed the best ability to quantify accurately the active content over the 80–120% active content range. The reliability of the NIR method was tested with new pilot batches of non-coated pharmaceutical pellets containing 90 and 110% of the usual active content, with blends of validation batches and industrial batches. All those batches were also analyzed by the HPLC reference method and relative errors were calculated: the results showed low relative errors in full accordance with the results obtained during the validation of the method, indicating the reliability of the NIR method and its interchangeability with the HPLC reference method.
Research center :
CIRM - Centre Interdisciplinaire de Recherche sur le Médicament - ULiège
Disciplines :
Pharmacy, pharmacology & toxicology
Author, co-author :
Mantanus, Jérôme ; Université de Liège - ULiège > Département de pharmacie > Chimie analytique
Ziemons, Eric ; Université de Liège - ULiège > Département de pharmacie > Chimie analytique
Lebrun, Pierre ; Université de Liège - ULiège > Département de pharmacie > Chimie analytique
Rozet, Eric ; Université de Liège - ULiège > Département de pharmacie > Chimie analytique
Klinkenberg, Régis; Galéphar Research Center M/F
Streel, Bruno; Galéphar Research Center M/F
Evrard, Brigitte ; Université de Liège - ULiège > Département de pharmacie > Pharmacie galénique
Hubert, Philippe ; Université de Liège - ULiège > Département de pharmacie > Chimie analytique
Language :
English
Title :
Active content determination of non-coated pharmaceutical pellets by near infrared spectroscopy: Method development, validation and reliability evaluation
Publication date :
2010
Journal title :
Talanta
ISSN :
0039-9140
eISSN :
1873-3573
Publisher :
Elsevier Science, Amsterdam, Netherlands
Volume :
80
Pages :
1750-1757
Peer reviewed :
Peer Reviewed verified by ORBi
Commentary :
J. Mantanus and E. Ziémons contributed equally to this work.
Luypaert J., Massart D.L., and Vander Heyden Y. Talanta 72 (2007) 865
Roggo Y., Chalus P., Maurer L., Lema-Martinez C., Edmond A., and Jent N. J. Pharm. Biomed. Anal. 44 (2007) 683
Burns D.A., and Ciurczak E.W. Handbook of Near-Infrared Analysis. 3rd ed. vol. 35 (2008), CRC Press, New York
American Food and Drug Administration (FDA). Guidance for Industry PAT-A Framework for Innovative Pharmaceutical Manufacturing and Quality Assurance (2004), FDA
International Conference on Harmonisation (ICH) of technical requirements for registration of pharmaceuticals for human use, Topic Q8: Pharmaceutical Development, Geneva, 2005.
Lopes J.A., Costa P.F., Alves T.P., and Menezes J.C. Chemo. Intel. Lab. Syst. 74 (2004) 269
Moes J.J., Ruijken M.M., Gout E., Frijlink H.W., and Ugwoke M.I. Int. J. Pharm. 357 (2008) 108
Bodson C., Dewé W., Hubert Ph., and Delattre L. J. Pharm. Biomed. Anal. 41 (2006) 783
Bodson C., Rozet E., Ziémons E., Evrard B., Hubert Ph., and Delattre L. J. Pharm. Biomed. Anal. 45 (2007) 356
Mantanus J., et al. Anal. Chim. Acta (2008) 10.1016/j.aca.2008.12.031
Rantanen J., Räsänen E., Antikainen O., Mannermaa J.-P., and Yliruusi J. Chemo. Intel. Lab. Syst. 56 (2001) 51
N. Sandler, J. Rantanen, J. Heinämäki, M. Römer, M. Marvola, J. Yliruusi, AAPS PharmSciTech. 6 (2) (2005) Article 26.
Ito M., Suzuki T., Yada S., Kusai A., Nakagami H., Yonemochi E., and Terada K. J. Pharm. Biomed. Anal. 47 (2008) 819
International Conference on Harmonization (ICH) of Technical Requirements for registration of Pharmaceuticals for human use, Topic Q2 (R1): Validation of Analytical Procedures: Text and Methodology, Geneva, 2005.
Hubert Ph., Nguyen-Huu J.J., Boulanger B., Chapuzet E., Chiap P., Cohen N., Compagnon P.A., Dewé W., Feinberg M., Lallier M., Laurentie M., Mercier N., Muzard G., Nivet C., and Valat L. J. Pharm. Biomed. Anal. 36 (2004) 579
Hubert Ph., Nguyen-Huu J.J., Boulanger B., Chapuzet E., Chiap P., Cohen N., Compagnon P.A., Dewé W., Feinberg M., Lallier M., Laurentie M., Mercier N., Muzard G., Nivet C., Valat L., and Rozet E. J. Pharm. Biomed. Anal. 45 (2007) 70
Hubert Ph., Nguyen-Huu J.J., Boulanger B., Chapuzet E., Cohen N., Compagnon P.-A., Dewé W., Feinberg M., Laurentie M., Mercier N., Muzard G., Valat L., and Rozet E. J. Pharm. Biomed. Anal. 45 (2007) 82
Hubert Ph., Chiap P., Crommen J., Boulanger B., Chapuzet E., Mercier N., Bervoas-Martin S., Chevalier P., Grandjean D., Lagorce P., Lallier M., Laparra M.C., Laurentie M., and Nivet J.C. Anal. Chim. Acta 391 (1999) 135
Rozet E., Ceccato A., Hubert C., Ziémons E., Oprean R., Rudaz S., Boulanger B., and Hubert P. J. Chromatogr. A 1158 (2007) 111
Rozet E., Morello R., Lecomte F., Martin G.B., Chiap P., Crommen J., Boos K.S., and Hubert P. J. Chromatogr. B 844 (2006) 251
Rozet E., Wascotte V., Lecouturier N., Préat V., Dewé W., Boulanger B., and Hubert Ph. Anal. Chim. Acta 591 (2007) 239
Rozet E., Hubert C., Ceccato A., Dewé W., Ziemons E., Moonen F., Michail K., Wintersteiger R., Streel B., Boulanger B., and Hubert Ph. J. Chromatogr. A 1158 (2007) 126
Feinberg M., Boulanger B., Dewé W., and Hubert Ph. Anal. Bioanal. Chem. 380 (2004) 502
International Conference on Harmonisation (ICH) of technical requirements for registration of pharmaceuticals for human use, Topic Q9: Quality Risk Management, Geneva, 2005.
European Medicines Agency, draft: guideline on the use of near infrared spectroscopy by the pharmaceutical industry and the data requirements for new submissions and variations, EMEA/CHMP/CVMP/QWP/17760/2009 Rev 1.